H U : Announcement of Determination of Terms of the Allotment of Stock Options (Stock Acquisition Rights)
December 27, 2021 at 02:17 am EST
Share
(Note) This summary document has been translated from the Japanese original for reference purposes only and does not cover all articles. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
December 27, 2021
Press Release
Company Name:
H.U. Group Holdings, Inc
Name of
Shigekazu Takeuchi
Representative:
President & CEO
Code Number:
4544, 1st Section of
Tokyo Stock Exchange
Contact:
Atsuko Murakami, CFO
Telephone No.:
+81-3-5909-3337
Announcement of Determination of Terms of the Allotment of Stock Options (Stock Acquisition Rights)
H.U. Group Holdings, Inc. (hereinafter, the Company) has announced that, with respect to the Stock Options resolved at the Board of Directors meeting held on November 26, 2021, undermined items have been determined as follows.
Total number of Stock Options (Stock Acquisition Rights)
612 rights
The value of assets to be contributed upon exercise of each stock acquisition right 292,400 yen per stock acquisition right (2,924 yen per share)
Paid-inamount for the stock acquisition rights
43,600 yen per stock acquisition right (436 yen per share)
Stock Acquisition Rights allotment recipients, number of recipients, and the number of stock acquisition rights to be allotted
Allotment Recipients
Number of Recipients
Number of Stock Acquisition
Rights to be Allotted
Employees of the Company
69 individuals
239
Directors of Subsidiaries
10 individuals
34
Employees of Subsidiaries
101 individuals
339
Attachments
Original Link
Original Document
Permalink
Disclaimer
Miraca Holdings Inc. published this content on 27 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 December 2021 07:16:05 UTC.
H.U. Group Holdings Inc, formerly Miraca Holdings Inc is a Japan-based holding company engaged in manufacture and sale of clinical test drugs, entrusted clinical examination and sterilization related business. The Company operates in four business segments. The Outsourced Clinical Testing segment accepts special tests from medical institutions. The Clinical Laboratory Medicine segment manufactures and sells clinical laboratory medicines and sells them to medical institutions and contract clinical laboratory companies. The Sterilization segment mainly entrusts the sterilization of medical equipment used for medical treatment in hospitals of large-scale hospitals and the related operations. The New Development & Others segment is involved in the homecare & welfare equipment business, self-medication & health insurance business, food & environment & cosmetics inspection business.
H.U. GROUP HOLDINGS, INC. 
